WC
CGEM icon

Wexford Capital’s Cullinan Oncology CGEM Stock Holding History

Wexford Capital’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,317
Closed -$31.5K – 404
2025
Q3 		$31.5K Sell
5,317
-13,409
-72% -$98.2K ﹤0.01% 358
2025
Q2 		$141K Buy
+18,726
New +$150K 0.04% 194

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wexford Capital's CGEM Position: Q4 2025 in Review

Wexford Capital sold out of Cullinan Oncology (CGEM) in Q4 2025, closing a stake of 5,317 shares — an estimated $31.5K sold.

Wexford Capital first reported a position in CGEM in Q2 2025 and held it in 2 quarters. The position peaked at $141K in Q2 2025. 153 funds tracked by Wall St. Rank hold CGEM as of Q4 2025.

  • Wexford Capital reported no remaining Cullinan Oncology position as of Q4 2025 after selling out during the quarter.
  • Wexford Capital sold 5,317 Cullinan Oncology shares in Q4 2025, an estimated $31.5K.
  • Wexford Capital first reported a position in Cullinan Oncology in Q2 2025 and held it in 2 quarters.
  • Wexford Capital's Cullinan Oncology position peaked at $141K in Q2 2025.
  • 153 funds tracked by Wall St. Rank held Cullinan Oncology as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.